Cai Jing Wang·2026-01-09 09:16Group 1 - Insilico Medicine announced a collaboration with Servier valued at $888 million focused on the discovery and development of innovative anti-cancer therapies [1] - Insilico will receive up to $32 million in upfront and milestone payments, leveraging its AI-driven drug development platform [1] - Servier will lead the clinical validation and commercialization of promising drug candidates globally [1] Group 2 - Weigao Blood Products announced a major asset restructuring involving the acquisition of 100% equity in Weigao Purui for approximately $8.511 billion [2] - Post-transaction, Weigao Purui will become a wholly-owned subsidiary, expanding the company's business into pharmaceutical packaging [2] - Weigao's shareholding in Weigao Blood Products will increase to 84.36%, maintaining absolute control [2] Group 3 - Earendil Labs (HuaShen ZhiYao) entered a strategic partnership with Sanofi worth up to $2.56 billion for the development of bispecific candidates targeting autoimmune and inflammatory diseases [3] - Earendil Labs will receive up to $160 million in upfront and milestone payments linked to early project outcomes [3] - The agreement includes tiered royalties based on net sales [3] Group 4 - WuXi AppTec announced that its controlling shareholders have reduced their stake by 2%, totaling 59.68 million shares [4] - The reduction was completed as per the previously disclosed plan, with the controlling shareholders holding 18.211% of the total shares before the reduction [4] Group 5 - Nanhua Biological announced plans for a significant asset restructuring to acquire 51% of Huize Pharmaceutical for cash [5] - The transaction is expected to constitute a major asset restructuring without involving share issuance or control changes [5] - Due diligence and negotiations are ongoing, with no formal agreement signed yet [5] Group 6 - Kangchen Pharmaceutical projected a net profit of between 145 million to 175 million yuan for 2025, representing a year-on-year increase of 243% to 315% [6] - The expected net profit excluding non-recurring gains is projected to be between 140 million to 170 million yuan, reflecting a significant increase from the previous year [6] Group 7 - Yilian Biotech signed a new exclusive licensing agreement with Roche for the YL201 project, with an upfront payment of $570 million [7] - The agreement allows Roche exclusive rights to develop and commercialize the YL201 project globally, excluding mainland China and certain regions [7] - This partnership builds on a successful collaboration on the YL211 project, aiming to accelerate the development of YL201 [7]